Cambridge, MA, USA, April 1, 2021
Colospan Ltd. is opening its US headquarters in Cambridge, MA.
The Israeli startup which develops novel and proprietary solutions for colorectal surgery is putting a major focus on its US operations to support its IDE approved, multi-center randomized trial currently enrolling rectal cancer patients in 9 participating hospitals across the United States.
Colospan offers rectal cancer patients a unique alternative to the diverting stoma by providing a temporary intraluminal bypass which is designed to reduce the contact of fecal materials with the anastomotic site. This temporary diversion solution is removed without surgery in under two weeks and aims to minimize post-operative complications for a comfortable recovery.
The goal of the prospective, controlled study is to create clinical data related to the safety, performance, and risk/benefit of the CG-100 device in the intended patient population.
“We chose Cambridge for the US HQ because it is widely known as the epicenter for medical research in Massachusetts””, says VP Clinical Affairs, Jonathan Elsner. “This, combined with the city’s high concentration of successful startups and openness to innovation, is what excites the team most about having a presence in Cambridge.”
